My Watchlist
Indicators
Local Stocks
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Vanqua Bio

Vanqua Bio Highlights Positive Interim Data from its Ongoing Phase 1b Clinical Trial of VQ-101, an Allosteric Activator of GCase for the Treatment of GBA-Parkinson’s and Related Disorders, at The International Congress of Parkinson’s Disease and Movement
From Vanqua Bio
Via GlobeNewswire
Vanqua Bio to Present at Upcoming Scientific Conferences
From Vanqua Bio
Via GlobeNewswire
Vanqua Bio to Present at the AD/PD™ 2025 International Conference
From Vanqua Bio
Via GlobeNewswire
Vanqua Bio to Present Pre-Clinical Data on VQ-201, a Next Generation C5aR1 Antagonist for the Treatment of Inflammatory Disorders
From Vanqua Bio
Via GlobeNewswire
Vanqua Bio Announces Positive Interim Results from Phase 1 Clinical Trial of VQ-101, an Orally Administered, Brain-Penetrant, Allosteric Activator of GCase for the Treatment of GBA-Parkinson’s and Related Disorders
From Vanqua Bio
Via GlobeNewswire
Vanqua Bio to Participate in Upcoming Scientific Conferences
From Vanqua Bio
Via GlobeNewswire
Vanqua Bio to Present at Inaugural GBA1 2024 Meeting
From Vanqua Bio
Via GlobeNewswire
Vanqua Bio Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating VQ-101, its Small Molecule GCase Activator for GBA-Parkinson’s Disease and Related Disorders
From Vanqua Bio
Via GlobeNewswire
Vanqua Bio to Present at the Stifel 2024 CNS Days Conference
From Vanqua Bio
Via GlobeNewswire
Vanqua Bio to Present Pre-Clinical Data on VQ-101, a Novel GCase Activator For The Treatment of GBA-Parkinson’s Disease
From Vanqua Bio
Via GlobeNewswire
Vanqua Bio Advances Clinical Candidate for Parkinson’s Disease, Expands Leadership Team to Support Further Development
From Vanqua Bio
Via GlobeNewswire
Vanqua Bio to Participate in the Leerink Partners Biopharma Private Company Connect
From Vanqua Bio
Via GlobeNewswire
Vanqua Bio to Present at the Stifel 2023 CNS Day Conference
From Vanqua Bio
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.